In last trading session, ReShape Lifesciences Inc. (NASDAQ:RSLS) saw 0.59 million shares changing hands with its beta currently measuring 0.01. Company’s recent per share price level of $0.24 trading at -$0.01 or -2.76% at ring of the bell on the day assigns it a market valuation of $3.15M. That closing price of RSLS’s stock is at a discount of -9233.33% from its 52-week high price of $22.40 and is indicating a premium of 20.83% from its 52-week low price of $0.19. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.77 million shares which gives us an average trading volume of 3.23 million if we extend that period to 3-months.
For ReShape Lifesciences Inc. (RSLS), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.72 in the current quarter.
ReShape Lifesciences Inc. (NASDAQ:RSLS) trade information
Upright in the red during last session for losing -2.76%, in the last five days RSLS remained trading in the red while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $0.24 price level, adding 7.34% to its value on the day. ReShape Lifesciences Inc.’s shares saw a change of -96.44% in year-to-date performance and have moved -0.21% in past 5-day. ReShape Lifesciences Inc. (NASDAQ:RSLS) showed a performance of 3.45% in past 30-days. Number of shares sold short was 1.67 million shares which calculate 0.19 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $4.00 to the stock, which implies a rise of 94.0% to its current value. Analysts have been projecting $4.00 as a low price target for the stock while placing it at a high target of $4.00. It follows that stock’s current price would drop -1566.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1566.67% for stock’s current value.
ReShape Lifesciences Inc. (RSLS) estimates and forecasts
The company is estimating its revenue growth to increase by 91.60% in the current quarter and calculating 49.40% increase in the next quarter. This year revenue growth is estimated to fall -14.20% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.7 million for the same. And 1 analysts are in estimates of company making revenue of $2.52 million in the next quarter that will end on Mar 2024. Company posted $3.11 million and $2.29 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -13.20% while estimating it to be 10.20% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 48.88% during past 5 years.
ReShape Lifesciences Inc. is more likely to be releasing its next quarterly report on November 08 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.